Familial Mediterranean Fever (FMF) is a hereditary auto-inflammatory disease. The symptoms are high fever, abdominal pain and arthralgia due to MEFV, a gene disorder. FMF requires a life-long treatment in which Colchicine is used. Colchicine prevents kidney failure due to the accumulation of amyloidosis, which is the primary cause of FMF (57%). M694V mutation in which the disease onsets at an earlier age, the severity is higher. In this study, an evaluation of the articles on FMF has been made. A total of 16,927 people were included in the study. 2,421 were females and 1,708 were males. A total of 625 pregnant women with FMF were included in three studies conducted on FMF and pregnancy. In other studies, other diseases such as Polyarteritis Nodosa (PAN), Celiac Disease, Immunoglobulin A Vasculitis /Henoch-Schönlein Purpura (IgAV/ HSP), Protracted Fibromyalgia Syndrome (PFMS) and Hidradenitis Supportive (HS) can be observed together with FMF. Although FMF has existed in Anatolia, Caucasia and the Middle East for several thousand years, it was recognized as a clinical entity in 1945. The disease was first published in Turkish medical literature in 1946. Its relationship with amyloidosis was documented in 1950’s. Colchicine was discovered to treat FMF in 1972. Its gene MEFV and proteins pyrin/marenostrinwere discovered in 1997. It was recently   found out that pyrin had some structural similarities to death domains of certain proteins taking part in apoptosis, and FMF was included in a new group of diseases which somewhat resembled each other with recurrent inflammatory attacks: the auto inflammatory diseases. There have been recent studies on the genetics and the treatment of FMF in Turkey.